Company: SCLXW
Filing Date: 2025-08-04
Form Type: S-1
Source: 0001193125-25-172703
Chunk: 525

Company: Scilex Holding Co
Filing Date: 2025-08-04
Form: S-1
Chunk 525
---
 2024 RDO Warrants”). The combined offering price (a) per share of Common Stock and accompanying December 2024 RDO Common Warrants was $ 20.65and (b) per December 2024 RDO Pre-FundedWarrant and accompanying December 2024 RDO Common Warrants was $ 20.6499. The aggregate gross proceeds to the Company from the December 2024 RDO were approximately $ 17.0million, before deducting offering fees and expenses. The Company intends to use the net proceeds from the December 2024 RDO for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. The Company accounted for the December 2024 RDO Common Warrants and December 2024 RDO Pre-FundedWarrants as liability classified instruments (see Note 4) and the StockBlock Warrants as an equity classified instrument. The StockBlock Warrants are recognized in additional paid-incapital in the Company’s consolidated balance sheets. The issuance costs allocated to the equity component are recorded as the reduction of the offering proceeds and the amounts allocated to the liability component are expensed as incurred within the selling, general and administrative expenses in the Company’s consolidated statement of operations. The fair value of StockBlock Warrants as of the date of issuance was $ 1.3million. On December 26, 2024, the December 2024 RDO Pre-FundedWarrants were exercised by the holder for total net proceeds of approximately $ 0.2million. F-42 As of December 31, 2024, there were 57,512,958December 2024 RDO Common Warrants , which are currently exercisable for an aggregate of up to 1,642,871shares of Common Stock outstanding,and 4,601,036StockBlock Warrants , which are currently exercisable for an aggregate of up to 131,472shares of Common Stockoutstanding. 10. Stock Incentive and E mployee Benefit Plan 2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan In June 2017, the Board of Directors of the Company adopted the Scilex Pharmaceuticals Inc. Equity Incentive Plan (the “Scilex Pharma 2017 Plan”). In connection with the